627 related articles for article (PubMed ID: 25523493)
1. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
[TBL] [Abstract][Full Text] [Related]
2. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Kunath F; Grobe HR; Rücker G; Motschall E; Antes G; Dahm P; Wullich B; Meerpohl JJ
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009266. PubMed ID: 24979481
[TBL] [Abstract][Full Text] [Related]
3. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Philippou YA; Kuntz GM; Konety BR; Gupta S; Lamb AD; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012816. PubMed ID: 30320443
[TBL] [Abstract][Full Text] [Related]
4. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
5. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
[TBL] [Abstract][Full Text] [Related]
6. [Nonsteroidal antiandrogenic monotherapy: compared to monotherapy with luteinizing hormone-releasing hormone agonists or surgical castration for advanced prostate cancer].
Kunath F; Schmidt S
Urologe A; 2015 Jan; 54(1):78-81. PubMed ID: 25631466
[No Abstract] [Full Text] [Related]
7. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
8. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
9. Safety of antiandrogen therapy for treating prostate cancer.
Ricci F; Buzzatti G; Rubagotti A; Boccardo F
Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.
Samson DJ; Seidenfeld J; Schmitt B; Hasselblad V; Albertsen PC; Bennett CL; Wilt TJ; Aronson N
Cancer; 2002 Jul; 95(2):361-76. PubMed ID: 12124837
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer.
Yang Y; Chen R; Sun T; Zhao L; Liu F; Ren S; Wang H; Lu X; Gao X; Xu C; Sun Y
Curr Oncol; 2019 Feb; 26(1):e39-e47. PubMed ID: 30853808
[TBL] [Abstract][Full Text] [Related]
12. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
Caubet JF; Tosteson TD; Dong EW; Naylon EM; Whiting GW; Ernstoff MS; Ross SD
Urology; 1997 Jan; 49(1):71-8. PubMed ID: 9000189
[TBL] [Abstract][Full Text] [Related]
13. Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F; Jakob JJ; Schmidt S; Meerpohl JJ; Blümle A; Schmucker C; Mayer B; Kunath F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD012548. PubMed ID: 34350976
[TBL] [Abstract][Full Text] [Related]
14. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
Gillatt D
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.
Kunath F; Borgmann H; Blümle A; Keck B; Wullich B; Schmucker C; Sikic D; Roelle C; Schmidt S; Wahba A; Meerpohl JJ
BMJ Open; 2015 Nov; 5(11):e008217. PubMed ID: 26567252
[TBL] [Abstract][Full Text] [Related]
16. Interventions for treating femoral shaft fractures in children and adolescents.
Madhuri V; Dutt V; Gahukamble AD; Tharyan P
Evid Based Child Health; 2014 Dec; 9(4):753-826. PubMed ID: 25504970
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review.
Kunath F; Keck B; Antes G; Wullich B; Meerpohl JJ
BMC Med; 2012 Aug; 10():96. PubMed ID: 22925442
[TBL] [Abstract][Full Text] [Related]
18. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
Sharma SK; Sharma A; Kadhiravan T; Tharyan P
Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
[TBL] [Abstract][Full Text] [Related]
19. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
Schmitt B; Wilt TJ; Schellhammer PF; DeMasi V; Sartor O; Crawford ED; Bennett CL
Urology; 2001 Apr; 57(4):727-32. PubMed ID: 11306391
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogens in the treatment of prostate cancer.
Wirth MP; Hakenberg OW; Froehner M
Eur Urol; 2007 Feb; 51(2):306-13; discussion 314. PubMed ID: 17007995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
